CO5241329A1 - Anticuerpos que son anti-idiotipicos para un anticuerpo que interfiere con el enlace de la region c 3 de ige al receptor de alta afinidad para ige. - Google Patents

Anticuerpos que son anti-idiotipicos para un anticuerpo que interfiere con el enlace de la region c 3 de ige al receptor de alta afinidad para ige.

Info

Publication number
CO5241329A1
CO5241329A1 CO00026468A CO00026468A CO5241329A1 CO 5241329 A1 CO5241329 A1 CO 5241329A1 CO 00026468 A CO00026468 A CO 00026468A CO 00026468 A CO00026468 A CO 00026468A CO 5241329 A1 CO5241329 A1 CO 5241329A1
Authority
CO
Colombia
Prior art keywords
ige
antibody
idiotipical
interferes
antibodies
Prior art date
Application number
CO00026468A
Other languages
English (en)
Inventor
Franz Kricek
Beda Stadler
Vogel Monique
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CO5241329A1 publication Critical patent/CO5241329A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un mimocuerpo, que es un fragmento de anticuerpo monoclonal recombinante anti-idiotípico : para el anticuerpo BSW17 (ECACC 96121916), el cual consiste en, o comprende, el dímero de cadena ligera, o uno de los dos fragmentos Fab de la Figura 4, en donde las regiones constantes de los mismos también cubren las modificaciones estéricas menores, tales como las que se encuentran en las variantes alotípicas.
CO00026468A 1999-04-14 2000-04-11 Anticuerpos que son anti-idiotipicos para un anticuerpo que interfiere con el enlace de la region c 3 de ige al receptor de alta afinidad para ige. CO5241329A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9908533.4A GB9908533D0 (en) 1999-04-14 1999-04-14 Organic compounds

Publications (1)

Publication Number Publication Date
CO5241329A1 true CO5241329A1 (es) 2003-01-31

Family

ID=10851525

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00026468A CO5241329A1 (es) 1999-04-14 2000-04-11 Anticuerpos que son anti-idiotipicos para un anticuerpo que interfiere con el enlace de la region c 3 de ige al receptor de alta afinidad para ige.

Country Status (29)

Country Link
US (1) US7041288B2 (es)
EP (1) EP1169353B1 (es)
JP (1) JP4109829B2 (es)
KR (1) KR100492202B1 (es)
CN (1) CN1268644C (es)
AR (1) AR029624A1 (es)
AT (1) ATE392437T1 (es)
AU (1) AU767712B2 (es)
BR (1) BR0009781A (es)
CA (1) CA2363991C (es)
CO (1) CO5241329A1 (es)
CZ (1) CZ20013673A3 (es)
DE (1) DE60038608T2 (es)
ES (1) ES2302693T3 (es)
GB (1) GB9908533D0 (es)
HK (1) HK1044544B (es)
HU (1) HUP0200713A2 (es)
IL (2) IL145507A0 (es)
MX (1) MXPA01010348A (es)
MY (1) MY141459A (es)
NO (1) NO20014936L (es)
PE (1) PE20010046A1 (es)
PL (1) PL350676A1 (es)
PT (1) PT1169353E (es)
RU (1) RU2253655C2 (es)
SK (1) SK14592001A3 (es)
TR (1) TR200102877T2 (es)
WO (1) WO2000063252A1 (es)
ZA (1) ZA200107906B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6913749B2 (en) * 1998-11-02 2005-07-05 Resistentia Pharmaceuticals Ab Immunogenic polypeptides for inducing anti-self IgE responses
GB0103174D0 (en) * 2001-02-08 2001-03-28 Smithkline Beecham Plc Novel method of treatment
EP1239032A1 (en) * 2001-03-02 2002-09-11 Société des Produits Nestlé S.A. Lactic acid bacteria as agents for treating and preventing allergy
SE0101093D0 (sv) 2001-03-28 2001-03-28 Pharmacia Diagnostics Ab Novel compound for treatment of allergy and asthma
US7604955B2 (en) 2001-08-13 2009-10-20 Swey-Shen Alex Chen Immunoglobulin E vaccines and methods of use thereof
TWI323265B (en) 2002-08-06 2010-04-11 Glaxo Group Ltd Antibodies
GB0306309D0 (en) 2003-03-19 2003-04-23 Glaxo Group Ltd Method of treatment
US8029783B2 (en) * 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
CN101062949B (zh) * 2006-04-26 2011-07-27 上海抗体药物国家工程研究中心有限公司 重组抗人IgE单克隆抗体及其制备方法和用途
US20080118524A1 (en) * 2006-10-20 2008-05-22 Stefan Persson Anti-IgE Vaccines
US7718772B2 (en) * 2006-12-14 2010-05-18 Schering-Plough Animal Health Corporation Canine thymic stromal lymphopoietin protein and uses thereof
PL3023438T3 (pl) 2009-09-03 2020-07-27 Merck Sharp & Dohme Corp. Przeciwciała anty-gitr
KR101660578B1 (ko) 2009-09-03 2016-09-27 화이자 백신스 엘엘씨 Ｐｃｓｋ９ 백신
US10214593B2 (en) 2013-04-02 2019-02-26 Samsung Electronics Co., Ltd. Anti-idiotype antibody against anti-c-MET antibody
WO2020176549A1 (en) * 2019-02-26 2020-09-03 Sorrento Therapeutics, Inc. Antigen binding proteins that bind bcma

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3479289D1 (en) 1983-11-07 1989-09-14 Wistar Inst Immune response to tumours and viruses induced by anti-idiotype antibodies
CA1341235C (en) 1987-07-24 2001-05-22 Randy R. Robinson Modular assembly of antibody genes, antibodies prepared thereby and use
EP0617127A1 (en) * 1987-12-31 1994-09-28 Tanox Biosystems, Inc. Antigenic epitopes on B cell-bound IgE Immunoglobulins
EP0512064B1 (en) 1990-01-23 1997-06-18 Tanox Biosystems, Inc. Extracellular segments of human ige immunoglobulin anchoring peptides and antibodies specific therefor
IT1238286B (it) 1990-03-26 1993-07-12 Dispositivo sensore di livello del liquido per caldaie a vapore.
US5512283A (en) 1990-07-06 1996-04-30 Allergene, Inc. Methods for the selective suppression of an immune response to dust mite der Pi
DE69332744T2 (de) 1992-09-30 2004-01-15 Scripps Research Inst Humaner neutralisierender monoklonaler antikörper gegen den die immunschwäche beim menschen hervorringenden virus
JP3421970B2 (ja) * 1996-03-01 2003-06-30 ノバルティス アクチエンゲゼルシャフト ペプチド免疫原
JPH11174A (ja) * 1997-06-13 1999-01-06 Asahi Breweries Ltd 酵母を用いた抗体Ｆａｂ断片の製造法
US5994511A (en) 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
EP1078099A4 (en) 1998-04-24 2005-02-09 Fang Fang IDENTIFICATION OF PEPTIDE LIGANDS OF TARGET PROTEINS BY THE TECHNIQUE OF ADDITIONAL BANKS OF TCLT TARGETS

Also Published As

Publication number Publication date
NO20014936L (no) 2001-12-03
KR100492202B1 (ko) 2005-06-03
NO20014936D0 (no) 2001-10-10
MY141459A (en) 2010-04-30
US20020141989A1 (en) 2002-10-03
PT1169353E (pt) 2008-07-14
CA2363991C (en) 2010-06-08
ES2302693T3 (es) 2008-08-01
ATE392437T1 (de) 2008-05-15
IL145507A0 (en) 2002-06-30
HUP0200713A2 (en) 2002-07-29
TR200102877T2 (tr) 2002-01-21
IL145507A (en) 2008-11-03
US7041288B2 (en) 2006-05-09
RU2253655C2 (ru) 2005-06-10
WO2000063252A1 (en) 2000-10-26
CN1346372A (zh) 2002-04-24
BR0009781A (pt) 2002-01-08
AU767712B2 (en) 2003-11-20
JP4109829B2 (ja) 2008-07-02
HK1044544A1 (en) 2002-10-25
PE20010046A1 (es) 2001-02-23
EP1169353A1 (en) 2002-01-09
GB9908533D0 (en) 1999-06-09
CN1268644C (zh) 2006-08-09
MXPA01010348A (es) 2002-10-23
ZA200107906B (en) 2003-08-27
CZ20013673A3 (cs) 2002-05-15
PL350676A1 (en) 2003-01-27
CA2363991A1 (en) 2000-10-26
EP1169353B1 (en) 2008-04-16
DE60038608D1 (de) 2008-05-29
DE60038608T2 (de) 2009-06-10
AR029624A1 (es) 2003-07-10
SK14592001A3 (sk) 2002-05-09
JP2002544125A (ja) 2002-12-24
KR20020007366A (ko) 2002-01-26
HK1044544B (zh) 2008-11-21
AU3966000A (en) 2000-11-02

Similar Documents

Publication Publication Date Title
CO5241329A1 (es) Anticuerpos que son anti-idiotipicos para un anticuerpo que interfiere con el enlace de la region c 3 de ige al receptor de alta afinidad para ige.
EA200500647A1 (ru) Антитела, связывающие клеточные полипептиды ca 125/0772p, и способы их применения
CO5470287A1 (es) Antagonistas recombinantes de il-18 utiles en el tratamiento de trastornos mediados por il-18
EE200700052A (et) Antikeha he v?i mitme apo-lipoproteiin B fragmendi vastu
EA200400510A1 (ru) Агенты, специфически связывающие ангиопоэтин-2
ES2168376T3 (es) Anticuerpos que activan un receptor de eritropoyetina.
RS80704A (en) ANTI- av?6.ANTIBODIES
ES2074701T3 (es) Anticuerpo recombinante especifico cd3.
PE20050727A1 (es) Anticuerpos dirigidos a c-met
WO1998036074A3 (en) Single and double chain antibodies to the egf receptor, derivates thereof and their use
HRP20090517T1 (en) Interleukin-10 antibodies
BR9809778A (pt) Polinucleotìdeo isolado, vetor de expressão, peptìdeo ou polipetìdeo isolado, anticorpo, processo para produzir o mesmo, fragmentos de anticorpos, anticorpos de cadeia única ou anticorpos humanizados, e, anticorpo anti-idiotìpico.
ES2181752T3 (es) Conjugados de agentes antitumorales de metiltritio y productos intermedios para su sintesis.
CR10134A (es) Anticuerpos para el receptor de factor de crecimiento y similar a la insulina (divisional exp. 7045)
EA200400526A1 (ru) Агенты, специфически связывающиеся с человеческим ангиопоэтином-2
UA89017C2 (uk) ЛЮДСЬКЕ АНТИТІЛО, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ЛЮДСЬКИМ TNFSF13b
CY1109093T1 (el) Πρωτεϊνες των υποδοχεων θηλαστικων, σχετικα αντιδραστηρια και σχετικες μεθοδοι
CY1115295T1 (el) Συνθεση για την θεραπεια παθολογιας συνδεομενης με msrv/herv-w
NO901046D0 (no) Rekombinat proteinreseptor.
PT759942E (pt) Receptor de interleucina-15
CY1109167T1 (el) Μεθοδος για την παρασκευη αυξητικης ορμονης και ανταγωνιστη αυτης εχοντας χαμηλοτερα επιπεδα ισομορφικων προσμειξεων αυτου
ES2141169T3 (es) Proceso para preparar elementos de ensayo.
ES2070820T3 (es) Anticuerpos monoclonales especificos de la apolipoproteina b, producidos por dos nuevos hibridomas.
PT90582A (pt) Anti-idiotype antibodies to anti-human high molecular weight-melanoma associated antigen
BR9910568A (pt) Anticorpos agonistas de receptor de g-csf e processo de seleção para os mesmos

Legal Events

Date Code Title Description
FD Application lapsed